• There are currently 133 vaccines under development for COVID -19, 10 of which are already in human clinical trials and 123 in preclinical trials.
• According to FIFARMA, it is possible that a vaccine may be ready by the end of 2020.
• The R&D industry grouped at FIFARMA has donated USD 25 million in medicines and medical protective equipment. USD 700 million in monetary donations. USD 40 million in in-kind donations.
Bogotá, June 2020. Rafael Andrés Díaz-Granados, Executive President of the Latin American Federation of the Pharmaceutical Industry (FIFARMA), reiterated the public commitment of global R&D companies to work closely with governments and other organizations to ensure that treatments and vaccines, once approved, are available and accessible to all patients in the region.
During the webinar “The role of innovation against COVID -19”, organized by the Association of Pharmaceutical Research and Development Laboratories (AFIDRO), Díaz-Granados said that the intellectual property system should not be considered as a barrier or a threat to access. On the contrary, intellectual property has allowed pharmaceutical companies to make investments in order to accelerate the processes of vaccines and treatments to face coronavirus.
“When COVID -19 pandemic arrived, innovative biopharmaceuticals already had an advanced starting point regarding possible solutions. Much of the ongoing work is based on existing molecular products and compounds, as well as the knowledge and research capabilities developed over many years, which is possible thanks to the support of intellectual property right protection worldwide”, he said.
According to the World Health Organization (WHO), there are formally 133 vaccines in development against COVID-19, 10 of them are already in human clinical trials and 123 in preclinical trials. Of such 10 candidates, there is one in phase 3 and the others are in phase 1 and 2. All FIFARMA member companies and 25 members of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) are working intensively hard on this race for the good of humankind.
In fact, most innovation companies joined the Gates Foundation initiative to accelerate the development of treatments and vaccines for COVID-19. In addition, project “Solidarity” has gathered more than 100 countries working together to find effective therapies against COVID-19 as quickly as possible. IFPMA members have also actively participated in this initiative where scientists are looking for potentially useful agents that can help with the development of new or reused treatments to fight the new coronavirus.
Yaneth Giha, AFIDRO’s Executive President, added that “this is an unprecedented joint effort between the pharmaceutical industry, government agencies and multilateral organizations to address this crisis, which is of everyone’s concern” she highlighted.
FIFARMA’s Executive President recalled that typically the development of a vaccine takes between 5 to 10 years. Now, in the face of the pandemic’s urgency, things are being carried out 80% faster than normal, ensuring that safety and efficacy standards are met. “Once this happens, we hope to ensure continuity in the production and supply chains. In fact, companies are already investing in infrastructure to accelerate production and ensure the rapid distribution of treatments and vaccines for the good of all patients” he said.